$82.68 -0.5 -0.6%
Last Trade - 9:00pm
| Market Cap | £13.27bn |
| Enterprise Value | £11.99bn |
| Revenue | £1.93bn |
| Position in Universe | 635th / 6851 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 753.8 | 1,106 | 1,536 | 1,882 | 2,159 | 2,667 | 2,899 | 3,482 | +28.8% | ||
| +1,689 | +242.9 | +39.9 | ||||||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.
| Last Annual | December 31st, 2020 |
| Last Interim | December 31st, 2020 |
| Incorporated | April 8, 1991 |
| Public Since | April 8, 1991 |
| No. of Shareholders: | 122 |
| No. of Employees: | 1,773 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | Nasdaq Composite , Nasdaq 100 , S&P Composite 1500 , S&P 500 , S&P 500 Health Care (sector), |
| Exchange | NASDAQ Global Select Market |
| Shares in Issue | 219,843,497 |
| Free Float | (0.0%) |
| Eligible for |
✓
ISAs
✓
SIPPs
|
| Address | 1801 Augustine Cut off, WILMINGTON, 19803-4404, United States |
| Web | https://www.incyte.com/ |
| Phone | +1 302 4986700 |
| Contact | Michael Booth (Vice President - Investor Relations) |
| Auditors | Ernst & Young LLP |
As of 9:00pm, shares in Incyte are trading at $82.68, giving the company a market capitalisation of £13.27bn. This share price information is delayed by 15 minutes.
Shares in Incyte are currently trading at $82.68 and the price has moved by -8.52% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Incyte price has moved by -37.91% over the past year.
Of the analysts with advisory recommendations for Incyte, there are there are currently 5 "buy" , 8 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Incyte is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Incyte is scheduled to issue upcoming financial results on the following dates:
Incyte does not currently pay a dividend.
Incyte does not currently pay a dividend.
Incyte does not currently pay a dividend.
To buy shares in Incyte you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Incyte are currently trading at $82.68, giving the company a market capitalisation of £13.27bn.
Here are the trading details for Incyte:
Based on an overall assessment of its quality, value and momentum, Incyte is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Incyte are currently priced at $82.68. At that level they are trading at 26.13% discount to the analyst consensus target price of 0.00.
Analysts covering Incyte currently have a consensus Earnings Per Share (EPS) forecast of 3.266 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Incyte. Over the past six months, the relative strength of its shares against the market has been -23.73%. At the current price of $82.68, shares in Incyte are trading at -6.72% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Incyte.
Incyte's management team is headed by:
Here are the top five shareholders of Incyte based on the size of their shareholding:
